The U.S. Vaccination Rate Continues To Slow

The U.S. Vaccination Rate Continues To Slow

Up next

10 breakthrough technologies to expect in 2026

Wanna know where tech is headed this year? MIT Technology Review has answers. They compile an annual list called "10 Breakthrough Technologies". Today, host Regina G. Barber speaks with executive editor Amy Nordrum about the list, and they get into everything from commercial spac ...  Show more

When is your brain actually an "adult"?

There’s this idea that something happens in the human brain when we turn 25. Suddenly, we can rent a car without fees. Make rational decisions. We may even regret some of our past… indiscretions. All because we’re developed…right? Well, a recent paper in the journal Nature sugges ...  Show more

Recommended Episodes

Third Vaccine On The Way, Fauci Hails 'Spectacular Results'
Consider This from NPR

A third COVID-19 vaccine could receive emergency use authorization from the Food and Drug Administration this month. The vaccine made by Johnson & Johnson is 66% effective in preventing moderate to severe disease, according to a global study. Combined with the two vaccines curren ...  Show more

Why U.S. Vaccinations Started Slow And What We Know About The New Coronavirus Variant
Consider This from NPR

Initially, U.S. officials predicted that as many as 20 million Americans would be fully vaccinated before the end of 2020. And while that many vaccine doses were distributed, only a fraction of them have been administered. The federal government has given states control over dist ...  Show more

Why Are U.S. Coronavirus Cases Falling? And Will the Trend Last?
The Daily

The number of new coronavirus cases in the United States is falling, but has the country turned a corner in the pandemic? And what kind of threats do the new variants pose to people and to the vaccine rollout?

Today, we discuss the latest in the quest to stamp out the pa ...

  Show more

A Vaccine Breakthrough
The Daily

It’s a dark time in the struggle with the coronavirus, particularly in the United States, where infections and hospitalizations have surged.

But amid the gloom comes some light: A trial by the drug maker Pfizer has returned preliminary results suggesting that its vaccine ...

  Show more